Injection of adipose allograft for hand arthritis treatment
Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand
This study is testing if injecting a special fat tissue into the small joints of the hand can help adults with early-stage arthritis feel less pain and move better.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05747469 on ClinicalTrials.gov |
What this trial studies
This research evaluates the safety and efficacy of injecting adipose allograft matrix (AAM) into the small joints of the hand for treating early-stage osteoarthritis. The study aims to determine if AAM can improve pain and disability while serving as a safer alternative to current treatments like autologous fat transfer. Patients over 18 with joint pain and radiographic evidence of osteoarthritis will undergo the procedure, with outcomes measured through pain scales, disability surveys, and range of motion assessments. Follow-up evaluations will assess both safety and patient satisfaction.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with joint pain in the hand and radiographic evidence of osteoarthritis.
Not a fit: Patients with prior interventions for the affected joint or those with inflammatory arthritis conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a safer and more effective option for patients suffering from hand osteoarthritis.
How similar studies have performed: While the use of adipose allografts in other contexts has shown promise, this specific application for hand osteoarthritis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients greater than 18 years, with presentation to the Cedars Sinai hand clinic for joint pain of the hand carpometacarpal, interphalangeal, proximal interphalangeal, and distal interphalangeal joints (CMC, IP, PIP or DIP joints). * Radiographic evidence of osteoarthritis. Exclusion Criteria: * Prior intervention for the presenting joint (either in the form of cortisone or hyaluronic acid injection or surgery). * Rheumatoid or other inflammatory arthritis condition * Collagen vascular disease * Pregnancy or breast-feeding * Congestive heart failure * Chronic obstructive pulmonary disease * Chronic renal failure * Those who had medication or oral supplements for the previous 4 weeks that could prolong bleeding time (e.g.; Aspirin, Plavix).
Where this trial is running
Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Meghan McCullough, MD — Cedars-Sinai Medical Center
- Study coordinator: Joel C Program Manager
- Email: joel.arnold@cshs.org
- Phone: (310) 423-4614
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.